HIV testing: the mutual rights and responsibilities of partners.

1808 www.thelancet.com Vol 370 December 1, 2007 7 Sakaguchi M, Miyazawa H, Inouye S. Specifi c IgE and IgG to gelatin in children with systemic cutaneous reactions to Japanese encephalitis vaccines. Allergy 2001; 56: 536–39. 8 WHO. Global Advisory Committee on Vaccine Safety, 9–10 June 2005: mouse brain-derived Japanese encephalitis. Wkly Epidemiol Rec 2005; 80: 241–48. 9 Tauber F, Kollaritsch H, Korinek M, et al. Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial. Lancet 2007; 370: 1847–53. 10 Ferguson M, Johnes S, Li L, Heath A, Barrett A. Eff ect of genomic variation in the challenge virus on the neutralization titres of recipients of inactivated JE vaccines—report of a collaborative study on PRNT50 assays for Japanese encephalitis virus (JE) antibodies. Biologicals 2007; published online Sept 24. DOI:10.1016/j.biologicals.2007.07.002. 11 German AC, Myint KSA, Mai NTH, et al. A preliminary neuropathological study of Japanese encephalitis in humans and a mouse model. Trans R Soc Trop Med Hyg 2006; 100: 1135–45. 12 Artenstein AW, Johnson C, Marbury TC, et al. A novel, cell culture-derived smallpox vaccine in vaccinia-naïve adults. Vaccine 2005; 23: 3301–09. 13 Monath TP, Guirakhoo F, Nichols R, et al. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, eff ect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J Infect Dis 2003; 188: 1213–30. 14 Tandan JB, Ohrr H, Sohn YM, et al. Single dose of SA 14-14-2 vaccine provides long-term protection against Japanese encephalitis: a case-control study in Nepalese children 5 years after immunization. Vaccine 2007; 25: 5041–45.